(50, 100, 200 mg/kg) could protect against the TNBS-caused colitis in a rat model by decreasing the levels of IL-33, IL-5, IL-13, IL-6 cytokines and expression of IL-33 and ST2 proteins to inhibit the IL-33/ST2 signaling pathway (Liang et al., 2020). The gene discussed is IL13; the disease is colitis.